ERS Genomics & Demeetra Enter Into CRISPR/Cas9 Licensing Agreement Demeetra to broaden synthetic biology and bioprocessing technology through combined CRISPR/Cas9 IP and Demeetra’s own dimeric Cas-CLOVER. Dublin, Ireland and Kentucky, USA, September 12: ERS Genomics Limited (‘ERS’) is pleased to announce a new license agreement with Demeetra AgBio (‘Demeetra’). This.
Read Full ArticleSchedule time with Dr. Ralph Vogelsang, Senior Director, Business Development & Licensing, ERS Genomics
‘Your journey with CRISPR begins with a license from ERS Genomics. I am delighted to be back at BIO 2023. If you would like to learn more about CRISPR/Cas9 and licensing, connect with me and let’s talk.’
